Alchemist Adjuvant Lung Cancer Trials – Clinical Stage IB, II, or IIIA, resectable, non-squamous

Protocol Number: Alliance A151216 – Central block submission for ALK/EGFR testing – OPEN TO ENROLLMENT
Protocol Number: Alliance A081105 – Erlotinib (supplied) vs. Placebo – OPEN TO ENROLLMENT
Protocol Number: Alliance E4512 – Crizotinib (supplied) vs. Placebo – OPEN TO ENROLLMENT
Protocol Number: Alliance E5142 – Phase 3 Study of Adjuvant Nivolumab After Surgical Resection and Adjuvant Chemotherapy Non-small Cell Lung Cancer – OPEN TO ENROLLMENT

Epacadostat, Pembrolizumab, Platinum-Based Chemotherapy

Protocol Number: USOncology 17080 (www.clinicaltrials.gov)
A Randomized, Phase 3 Study of the Combinatin of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer – OPEN TO ENROLLMENT

Mocetinostat (HDAC Inhibitor, Durvalumab (PD-L1 Inhibitor)

Protocol Number: USOncology 17040 (www.clinicaltrials.gov)
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination with PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer – OPEN TO ENROLLMENT